

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
3.3	28.09.2024	809499-00020	Date of first issue: 15.07.2016

### SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1	Product identifier Trade name	:	Orbifloxacin Solid Formulation
1.2	Relevant identified uses of th	he s	ubstance or mixture and uses advised against
	Use of the Sub- stance/Mixture	:	Veterinary product
	Recommended restrictions on use	:	Not applicable
1.3	Details of the supplier of the	saf	ety data sheet
	Company	:	MSD Kilsheelan Clonmel Tipperary, IE
	Telephone	:	353-51-601000
	E-mail address of person responsible for the SDS	:	EHSDATASTEWARD@msd.com

### 1.4 Emergency telephone number

+1-908-423-6000

## **SECTION 2: Hazards identification**

## 2.1 Classification of the substance or mixture

#### Classification (REGULATION (EC) No 1272/2008)

Reproductive toxicity, Category 2

H361d: Suspected of damaging the unborn child.

### 2.2 Label elements

## Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms	:	
Signal word	:	Warning
Hazard statements	:	H361d Suspected of damaging the unborn child.
Precautionary statements	:	<b>Prevention:</b> P201 Obtain special instructions before use.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Orbifloxacin Solid Formulation**

Version 3.3	Revision Date: 28.09.2024	SDS Number: 809499-00020	Date of last issue: 06.04.2024 Date of first issue: 15.07.2016	

P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

#### **Response:**

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

#### Storage:

P405 Store locked up.

Hazardous components which must be listed on the label: Orbifloxacin

## 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation. Contact with dust can cause mechanical irritation or drying of the skin. May form explosive dust-air mixture during processing, handling or other means.

## **SECTION 3: Composition/information on ingredients**

#### 3.2 Mixtures

#### Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Orbifloxacin	113617-63-3	Repr. 2; H361d	>= 3 - < 10

For explanation of abbreviations see section 16.

:

#### **SECTION 4: First aid measures**

#### 4.1 Description of first aid measures

General advice

In the case of accident or if you feel unwell, seek medical advice immediately.

When symptoms persist or in all cases of doubt seek medical

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878

# **Orbifloxacin Solid Formulation**

Version 3.3	Revision Date: 28.09.2024		9499-00020	Date of last issue: 06.04.2024 Date of first issue: 15.07.2016		
			advice.			
Prote	ction of first-aiders	:	and use the recor	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).		
lf inha	aled	:	If inhaled, remove Get medical atten			
In case of skin contact		:	In case of contact, immediately flush skin with soap and pler of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.			
In cas	se of eye contact	:	If in eyes, rinse w Get medical atten	ell with water. tion if irritation develops and persists.		
lf swa	allowed	:	Get medical atten	NOT induce vomiting. tion. oughly with water.		
4.2 Most i	mportant symptoms a	nd e	effects, both acute	e and delayed		
Risks	i	:	Suspected of dan	naging the unborn child.		
			the skin.	can cause mechanical irritation or drying of the eyes can lead to mechanical irritation.		
4.3 Indica	tion of any immediate	med	lical attention and	special treatment needed		
Treat	ment	:	Treat symptomati	cally and supportively.		
SECTION	N 5: Firefighting meas	sur	es			
5.1 Exting	uishing media					
Suital	ble extinguishing media	:	Water spray Alcohol-resistant Carbon dioxide (C Dry chemical			
Unsu media	itable extinguishing a	:	None known.			
5.2 Specia	al hazards arising from	the	substance or mi	xture		
-	ific hazards during fire-	:	Avoid generating concentrations, a potential dust exp	dust; fine dust dispersed in air in sufficient nd in the presence of an ignition source is a		



# Orbifloxacin Solid Formulation

Ver 3.3	sion	Revision Date: 28.09.2024		9499-00020	Date of last issue: 06.04.2024 Date of first issue: 15.07.2016
	Hazard ucts	ous combustion prod-	:	Carbon oxides Nitrogen oxides (I Metal oxides	NOx)
5.3		for firefighters protective equipment ighters	:		e, wear self-contained breathing apparatus. rective equipment.
	Specific ods	c extinguishing meth-	:	cumstances and t Use water spray t	measures that are appropriate to local cir- he surrounding environment. o cool unopened containers. ged containers from fire area if it is safe to do

## **SECTION 6: Accidental release measures**

6.1 Personal precautions, protective equipment and emergency procedures				
Personal precautions :	Use personal protective equipment. Follow safe handling advice (see section 7) and personal pro- tective equipment recommendations (see section 8).			
6.2 Environmental precautions				
Environmental precautions :	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.			
6.3 Methods and material for contain	inment and cleaning up			
Methods for cleaning up :	<ul> <li>Sweep up or vacuum up spillage and collect in suitable container for disposal.</li> <li>Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).</li> <li>Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.</li> <li>Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.</li> <li>Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.</li> </ul>			

## 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.



# **Orbifloxacin Solid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
3.3	28.09.2024	809499-00020	Date of first issue: 15.07.2016

## **SECTION 7: Handling and storage**

#### 7.1 Precautions for safe handling Technical measures Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres. Local/Total ventilation Use only with adequate ventilation. : Do not breathe dust. Advice on safe handling : Do not swallow. Avoid contact with eves. Avoid prolonged or repeated contact with skin. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the environment. If exposure to chemical is likely during typical use, provide eye Hygiene measures flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls. 7.2 Conditions for safe storage, including any incompatibilities : Keep in properly labelled containers. Store locked up. Store in Requirements for storage areas and containers accordance with the particular national regulations. Advice on common storage : Do not store with the following product types: Strong oxidizing agents

#### 7.3 Specific end use(s)

Specific use(s)

No data available

## **SECTION 8: Exposure controls/personal protection**

#### 8.1 Control parameters

## **Occupational Exposure Limits**

Dust

5 mg/m3 Value type (Form of exposure): TWA (respirable dust) Basis: FOR-2011-12-06-1358



# **Orbifloxacin Solid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
3.3	28.09.2024	809499-00020	Date of first issue: 15.07.2016

10 mg/m3

Value type (Form of exposure): TWA (total dust) Basis: FOR-2011-12-06-1358

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Orbifloxacin	113617-63- 3	TWA	0.2 mg/m3 (OEB 2)	Internal

#### 8.2 Exposure controls

#### **Engineering measures**

Use feasible engineering controls to minimize exposure to compound. All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Personal protective equipm	nent	
Eye/face protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Hand protection Material	:	Chemical-resistant gloves
Skin and body protection Respiratory protection	:	Work uniform or laboratory coat. If adequate local exhaust ventilation is not available or expo- sure assessment demonstrates exposures outside the rec- ommended guidelines, use respiratory protection. Equipment should conform to NS EN 143
Filter type	:	Particulates type (P)

## **SECTION 9: Physical and chemical properties**

## 9.1 Information on basic physical and chemical properties

Physical state	:	powder
Colour	:	No data available
Odour	:	No data available
Odour Threshold	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, han- dling or other means.



# **Orbifloxacin Solid Formulation**

Ver 3.3	sion	Revision Date: 28.09.2024		S Number: 0499-00020	Date of last issue: 06.04.2024 Date of first issue: 15.07.2016
	Flamma	ability (liquids)	:	No data available	9
		explosion limit / Upper bility limit	:	No data available	)
		explosion limit / Lower bility limit	:	No data available	)
	Flash p	oint	:	Not applicable	
	Auto-ig	nition temperature	:	No data available	
	Decom	position temperature	:	No data available	9
	рН		:	No data available	9
	Viscosi Visc	ty :osity, kinematic	:	No data available	
	Solubili Wat	ty(ies) er solubility	:	No data available	9
	Partition octanol	n coefficient: n- /water	:	No data available	
	Vapour	pressure	:	No data available	9
	Relative	e density	:	No data available	9
	Density	,	:	No data available	
	Relative	e vapour density	:	No data available	
		characteristics icle size	:	No data available	
9.2		formation			
	Explosi		:	Not explosive	
		ng properties	:		r mixture is not classified as oxidizing.
	Evapor	ation rate	:	No data available	
	Molecu	lar weight	:	No data available	



Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
3.3	28.09.2024	809499-00020	Date of first issue: 15.07.2016

## **SECTION 10: Stability and reactivity**

#### 10.1 Reactivity

Not classified as a reactivity hazard.

#### 10.2 Chemical stability

Stable under normal conditions.

## 10.3 Possibility of hazardous reactions

Hazardous reactions	<ul> <li>May form explosive dust-air mixture during processing, han- dling or other means.</li> <li>Can react with strong oxidizing agents.</li> </ul>
10.4 Conditions to avoid	
Conditions to avoid	: Heat, flames and sparks.

Conditions to avoid	: Heat, names and spark	-
	Avoid dust formation.	

#### 10.5 Incompatible materials

Materials to avoid : Oxidizing agents

#### **10.6 Hazardous decomposition products**

No hazardous decomposition products are known.

## **SECTION 11: Toxicological information**

#### 11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of	:	Inhalation
exposure		Skin contact
		Ingestion
		Eye contact

#### Acute toxicity

Not classified based on available information.

#### **Components:**

## Orbifloxacin:

Acute oral toxicity	:	LD50 (Rat): > 3.000 mg/kg Remarks: No mortality observed at this dose.
		LD50 (Mouse): > 2.000 mg/kg Remarks: No mortality observed at this dose.
		LD50 (Dog): > 600 mg/kg Symptoms: Vomiting Remarks: No mortality observed at this dose.
Acute inhalation toxicity	:	Remarks: No data available
Acute dermal toxicity	:	Remarks: No data available



# **Orbifloxacin Solid Formulation**

Versio 3.3	on	Revision Date: 28.09.2024		0S Number: 9499-00020	Date of last issue: 06.04.2024 Date of first issue: 15.07.2016
		oxicity (other routes of stration)	:	LD50 (Rat): > 200 Application Route	
				LD50 (Mouse): 50 Application Route	
				LD50 (Rat): 233 r Application Route	
				LD50 (Mouse): 25 Application Route	

#### Skin corrosion/irritation

Not classified based on available information.

#### Components:

#### Orbifloxacin:

Species	:	Rabbit
Method	:	Draize Test
Result	:	No skin irritation

#### Serious eye damage/eye irritation

Not classified based on available information.

#### **Components:**

#### Orbifloxacin:

Species	:	Rabbit
Method	:	Draize Test
Result	:	Mild eye irritation

#### Respiratory or skin sensitisation

## Skin sensitisation

Not classified based on available information.

#### **Respiratory sensitisation**

Not classified based on available information.

## Components:

#### Orbifloxacin:

Test Type	:	Maximisation Test
Exposure routes	:	Dermal
Species	:	Guinea pig
Result	:	Not a skin sensitizer.

## Germ cell mutagenicity

Not classified based on available information.



Versio 3.3	on Revision Date: 28.09.2024		DS Number: 9499-00020	Date of last issue: 06.04.2024 Date of first issue: 15.07.2016
<u>c</u>	Components:			
c	Drbifloxacin:			
G	Genotoxicity in vitro	:	Test Type: Bacter Result: equivocal	rial reverse mutation assay (AMES)
			Test Type: Mouse Result: positive	e Lymphoma
			Test Type: Chron Test system: Hun Result: positive	nosomal aberration nan lymphocytes
G	Genotoxicity in vivo	:	Test Type: Micror Species: Mouse Cell type: Bone m Application Route Result: negative	
			Test Type: unsch Species: Rat Cell type: Liver ce Application Route Result: negative	
	Germ cell mutagenicity- As- essment	:	Weight of evidend cell mutagen.	ce does not support classification as a germ
c	Carcinogenicity			

Not classified based on available information.

#### **Components:**

## Orbifloxacin:

Species Application Route Exposure time NOAEL Result		Rat Oral 2 Years 200 mg/kg body weight negative
Species Application Route Exposure time NOAEL Result	: : : : :	Mouse Oral 2 Years 200 mg/kg body weight negative

#### **Reproductive toxicity**

Suspected of damaging the unborn child.

#### Components:

#### Orbifloxacin:

## SAFETY DATA SHEET

Target Organs

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Orbifloxacin Solid Formulation**

Version 3.3	Revision Date: 28.09.2024	SDS Number: 809499-00020	Date of last issue: 06.04.2024 Date of first issue: 15.07.2016
Effec	ts on fertility	Species: R Application General Tc Early Embr weight	Two-generation reproduction toxicity study at Route: Oral xicity - Parent: NOAEL: 50 mg/kg body weight yonic Development: NOAEL: 50 mg/kg body adverse effects
Effec ment	ts on foetal develop-	Species: R Application Embryo-foe Result: No	Route: Oral etal toxicity: LOAEL: 333 mg/kg body weight teratogenic effects, Embryotoxic effects and ad- ts on the offspring were detected only at high ma-
		Species: R Application General To Embryo-foe Result: No toxic effects	Route: Oral exicity Maternal: NOAEL: 20 mg/kg body weight etal toxicity: NOAEL: 60 mg/kg body weight effects on early embryonic development, Embryo- s and adverse effects on the offspring were detect- nigh maternally toxic doses, Reduced maternal
		Species: D Application Developme	Development og Route: Oral ental Toxicity: LOAEL: 2,5 mg/kg body weight ects on postnatal development, Skeletal malfor-
Repro sessr	oductive toxicity - As- nent	: Some evide animal exp	ence of adverse effects on development, based on eriments.
Not c STO	<b>Γ - single exposure</b> lassified based on avai <b>Γ - repeated exposure</b> lassified based on avai		
Repe	ated dose toxicity		
Com	ponents:		
Orbif	loxacin:		
Expo	EL	: Rat : 20 mg/kg : 80 mg/kg : Oral : 3 Months	r Kidney soleen

## SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Orbifloxacin Solid Formulation**

Version Revision Date: 3.3 28.09.2024	SDS Number: 809499-00020	Date of last issue: 06.04.2024 Date of first issue: 15.07.2016			
Species NOAEL LOAEL Application Route Exposure time	: Mouse : 80 mg/kg : 250 mg/kg : Oral : 3 Months				
Species NOAEL LOAEL Application Route Exposure time Target Organs Symptoms Remarks	<ul> <li>Juvenile dog</li> <li>50 mg/kg</li> <li>250 mg/kg</li> <li>Oral</li> <li>14 Days</li> <li>Heart, Bone</li> <li>Gastrointestinal of mortality observed</li> </ul>				
Species NOAEL LOAEL Application Route Exposure time Target Organs Remarks	<ul> <li>Juvenile dog</li> <li>2 mg/kg</li> <li>3 mg/kg</li> <li>Oral</li> <li>90 Days</li> <li>Bone</li> <li>No significant ad</li> </ul>	verse effects were reported			
Species NOAEL Application Route Exposure time	: Dog : 37,5 mg/kg : Oral : 30 Days				
Species NOAEL LOAEL Application Route Exposure time Symptoms	: Cat : 7,5 mg/kg : 22,5 mg/kg : Oral : 1 Months : Gastrointestinal o	disturbance			
	Not classified based on available information.				
11.2 Information on other hazar Endocrine disrupting prope					

#### Product:

Assessment

: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.



# **Orbifloxacin Solid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
3.3	28.09.2024	809499-00020	Date of first issue: 15.07.2016

#### Experience with human exposure

### Components:

#### Orbifloxacin:

Ingestion

Symptoms: central nervous system effects, Gastrointestinal disturbance, liver function change, anaphylaxis, Rash Remarks: May cause photosensitisation.

## **SECTION 12: Ecological information**

#### 12.1 Toxicity

No data available

## 12.2 Persistence and degradability

No data available

### 12.3 Bioaccumulative potential

No data available

## 12.4 Mobility in soil

No data available

### 12.5 Results of PBT and vPvB assessment

#### Product:

Assessment

: This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

#### 12.6 Endocrine disrupting properties

## Product:

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

## 12.7 Other adverse effects

No data available

### **SECTION 13: Disposal considerations**

#### 13.1 Waste treatment methods

Product

Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.



Version 3.3	Revision Date: 28.09.2024	SDS Number:Date of last issue: 06.04.2024809499-00020Date of first issue: 15.07.2016
Conta	aminated packaging	<ul> <li>Do not dispose of waste into sewer.</li> <li>Empty containers should be taken to an approved waste han dling site for recycling or disposal.</li> <li>If not otherwise specified: Dispose of as unused product.</li> </ul>
SECTION	N 14: Transport info	rmation
1/1 1 UN n	umber or ID number	
ADN		Not regulated as a desperate good
		: Not regulated as a dangerous good
ADR RID		: Not regulated as a dangerous good
		: Not regulated as a dangerous good
IMDG IATA		<ul> <li>Not regulated as a dangerous good</li> <li>Not regulated as a dangerous good</li> </ul>
	proper shipping name	: Not regulated as a dangerous good
-	oper snipping name	
ADN		: Not regulated as a dangerous good
ADR		: Not regulated as a dangerous good
RID		: Not regulated as a dangerous good
IMDO		: Not regulated as a dangerous good
		: Not regulated as a dangerous good
14.3 Tran	sport hazard class(es	)
ADN		: Not regulated as a dangerous good
ADR		: Not regulated as a dangerous good
RID		: Not regulated as a dangerous good
IMDO	6	: Not regulated as a dangerous good
ΙΑΤΑ		: Not regulated as a dangerous good
14.4 Pack	ing group	
ADN		: Not regulated as a dangerous good
ADR		: Not regulated as a dangerous good
RID		: Not regulated as a dangerous good
IMDO	3	: Not regulated as a dangerous good
ΙΑΤΑ	(Cargo)	: Not regulated as a dangerous good
ΙΑΤΑ	(Passenger)	: Not regulated as a dangerous good
	ronmental hazards egulated as a dangerou	is good
-	<b>ial precautions for us</b>	er

14.7 Maritime transport in bulk according to IMO instruments



Version 3.3	Revision Date: 28.09.2024	SDS Number: 809499-00020	Date of last issue: 06.04.2024 Date of first issue: 15.07.2016	
Rema	arks	: Not applicable	for product as supplied.	

## **SECTION 15: Regulatory information**

#### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII)	:	Not applicable
REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59).	:	Not applicable
REACH - List of substances subject to authorisation (Annex XIV)	:	Not applicable
Regulation (EC) on substances that deplete the ozone layer	:	Not applicable
Regulation (EU) 2019/1021 on persistent organic pollu- tants (recast)	:	Not applicable
Regulation (EU) No 649/2012 of the European Parlia- ment and the Council concerning the export and import of dangerous chemicals	:	Not applicable
Seveso III: Directive 2012/18/EU of the European Parlian	nent	and of the Council on the

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.

Not applicable

#### Other regulations:

Note the Working Environment Act § 4-1 and § 4-2 on requirements for the employer to protect pregnant employees against discomfort and injury as a result of the work situation and the working environment.

#### The components of this product are reported in the following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

#### 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

#### **SECTION 16: Other information**

Other information	:	Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.
Full text of H-Statements H361d	:	Suspected of damaging the unborn child.
Full text of other abbreviatio	ns	
Repr. FOR-2011-12-06-1358	:	Reproductive toxicity Norway. Occupational Exposure limits



Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
3.3	28.09.2024	809499-00020	Date of first issue: 15.07.2016

FOR-2011-12-06-1358 / : Long term exposure limit TWA

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

#### Further information

Sources of key data used to :	Internal technical data, data from raw material SDSs, OECD
compile the Safety Data	eChem Portal search results and European Chemicals Agen-
Sheet	cy, http://echa.europa.eu/

#### **Classification of the mixture:**

Repr. 2

H361d

**Classification procedure:** 

Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their



Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
3.3	28.09.2024	809499-00020	Date of first issue: 15.07.2016

intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NO / EN